Biodexa Pharmaceuticals (BDRX) Retained Earnings (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) reported Retained Earnings of -$207.3 million for Q4 2025, down 7.35% on a YoY basis from -$223.7 million in Q4 2024, and down 0.79% sequentially from -$205.6 million in Q2 2025.
Biodexa Pharmaceuticals (BDRX) Retained Earnings (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 13 years of Retained Earnings data on file, last reported at -$207.3 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 7.35% year-over-year to -$207.3 million; the trailing twelve-month figure through Dec 2025 stood at -$207.3 million (down 7.35% YoY), and the FY2025 full-year result was -$205.4 million, down 6.4% from the prior year.
- Retained Earnings slipped to -$207.3 million in Q4 2025, from -$205.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$158.7 million in Q4 2022 to a low of -$207.3 million in Q4 2025.
- A 5-year average of -$181.7 million and a median of -$177.6 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings dropped 20.04% in 2021 and rose 7.86% in 2022, its largest moves.
- Tracing BDRX's Retained Earnings over 5 years: stood at -$172.3 million in 2021, then climbed by 7.86% to -$158.7 million in 2022, then dropped by 13.19% to -$179.7 million in 2023, then retreated by 7.45% to -$193.1 million in 2024, then fell by 7.35% to -$207.3 million in 2025.
- Business Quant data shows BDRX's Retained Earnings at -$207.3 million in Q4 2025, -$205.6 million in Q2 2025, and -$193.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | -207.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -207.25 Mn |
| Jun 30, 2025 | -205.62 Mn |
| Dec 31, 2024 | -193.07 Mn |
| Jun 30, 2024 | -186.66 Mn |
| Dec 31, 2023 | -179.68 Mn |
| Jun 30, 2023 | -173.91 Mn |
| Dec 31, 2022 | -158.74 Mn |
| Jun 30, 2022 | -164.67 Mn |
| Dec 31, 2021 | -172.28 Mn |
| Jun 30, 2021 | -175.48 Mn |
| Dec 31, 2020 | -161.67 Mn |
| Jun 30, 2020 | -146.19 Mn |
| Dec 31, 2019 | -128.37 Mn |
| Jun 30, 2019 | -121.06 Mn |
| Dec 31, 2018 | -115.45 Mn |
| Jun 30, 2018 | -117.38 Mn |
| Dec 31, 2017 | -99.12 Mn |
| Jun 30, 2017 | -86.73 Mn |
| Dec 31, 2016 | -73.49 Mn |
| Jun 30, 2016 | -67.90 Mn |